Ranolazine, Ethnicity and the Metabolic Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT01304095

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01304095
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01304095. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine, Ethnicity and the Metabolic Syndrome
Acronym
REMS
Condition
Angina
Intervention (Drug)
Ranolazine
Lead sponsor
Atlanta Heart Specialists, LLC (class: other)
Collaborator
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01304095
Content hash
2eee1cc3246e5210f7f2d96fe4b925604e4652c8c776267ebc4cdd72b8bda665